Cargando…

Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study

BACKGROUND: Although the validity and safety of antipsychotic polypharmacy remains unclear, it is commonplace in the treatment of schizophrenia. This study aimed to investigate the degree that antipsychotic polypharmacy contributed to metabolic syndrome in outpatients with schizophrenia, after adjus...

Descripción completa

Detalles Bibliográficos
Autores principales: Misawa, Fuminari, Shimizu, Keiko, Fujii, Yasuo, Miyata, Ryouji, Koshiishi, Fumio, Kobayashi, Mihoko, Shida, Hirokazu, Oguchi, Yoshiyo, Okumura, Yasuyuki, Ito, Hiroto, Kayama, Mami, Kashima, Haruo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155482/
https://www.ncbi.nlm.nih.gov/pubmed/21791046
http://dx.doi.org/10.1186/1471-244X-11-118
_version_ 1782210122269851648
author Misawa, Fuminari
Shimizu, Keiko
Fujii, Yasuo
Miyata, Ryouji
Koshiishi, Fumio
Kobayashi, Mihoko
Shida, Hirokazu
Oguchi, Yoshiyo
Okumura, Yasuyuki
Ito, Hiroto
Kayama, Mami
Kashima, Haruo
author_facet Misawa, Fuminari
Shimizu, Keiko
Fujii, Yasuo
Miyata, Ryouji
Koshiishi, Fumio
Kobayashi, Mihoko
Shida, Hirokazu
Oguchi, Yoshiyo
Okumura, Yasuyuki
Ito, Hiroto
Kayama, Mami
Kashima, Haruo
author_sort Misawa, Fuminari
collection PubMed
description BACKGROUND: Although the validity and safety of antipsychotic polypharmacy remains unclear, it is commonplace in the treatment of schizophrenia. This study aimed to investigate the degree that antipsychotic polypharmacy contributed to metabolic syndrome in outpatients with schizophrenia, after adjustment for the effects of lifestyle. METHODS: A cross-sectional survey was carried out between April 2007 and October 2007 at Yamanashi Prefectural KITA hospital in Japan. 334 patients consented to this cross-sectional study. We measured the components consisting metabolic syndrome, and interviewed the participants about their lifestyle. We classified metabolic syndrome into four groups according to the severity of metabolic disturbance: the metabolic syndrome; the pre-metabolic syndrome; the visceral fat obesity; and the normal group. We used multinomial logistic regression models to assess the association of metabolic syndrome with antipsychotic polypharmacy, adjusting for lifestyle. RESULTS: Seventy-four (22.2%) patients were in the metabolic syndrome group, 61 (18.3%) patients were in the pre-metabolic syndrome group, and 41 (12.3%) patients were in visceral fat obesity group. Antipsychotic polypharmacy was present in 167 (50.0%) patients. In multinomial logistic regression analyses, antipsychotic polypharmacy was significantly associated with the pre-metabolic syndrome group (adjusted odds ratio [AOR], 2.348; 95% confidence interval [CI], 1.181-4.668), but not with the metabolic syndrome group (AOR, 1.269; 95%CI, 0.679-2.371). CONCLUSIONS: These results suggest that antipsychotic polypharmacy, compared with monotherapy, may be independently associated with an increased risk of having pre-metabolic syndrome, even after adjusting for patients' lifestyle characteristics. As metabolic syndrome is associated with an increased risk of cardiovascular mortality, further studies are needed to clarify the validity and safety of antipsychotic polypharmacy.
format Online
Article
Text
id pubmed-3155482
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31554822011-08-13 Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study Misawa, Fuminari Shimizu, Keiko Fujii, Yasuo Miyata, Ryouji Koshiishi, Fumio Kobayashi, Mihoko Shida, Hirokazu Oguchi, Yoshiyo Okumura, Yasuyuki Ito, Hiroto Kayama, Mami Kashima, Haruo BMC Psychiatry Research Article BACKGROUND: Although the validity and safety of antipsychotic polypharmacy remains unclear, it is commonplace in the treatment of schizophrenia. This study aimed to investigate the degree that antipsychotic polypharmacy contributed to metabolic syndrome in outpatients with schizophrenia, after adjustment for the effects of lifestyle. METHODS: A cross-sectional survey was carried out between April 2007 and October 2007 at Yamanashi Prefectural KITA hospital in Japan. 334 patients consented to this cross-sectional study. We measured the components consisting metabolic syndrome, and interviewed the participants about their lifestyle. We classified metabolic syndrome into four groups according to the severity of metabolic disturbance: the metabolic syndrome; the pre-metabolic syndrome; the visceral fat obesity; and the normal group. We used multinomial logistic regression models to assess the association of metabolic syndrome with antipsychotic polypharmacy, adjusting for lifestyle. RESULTS: Seventy-four (22.2%) patients were in the metabolic syndrome group, 61 (18.3%) patients were in the pre-metabolic syndrome group, and 41 (12.3%) patients were in visceral fat obesity group. Antipsychotic polypharmacy was present in 167 (50.0%) patients. In multinomial logistic regression analyses, antipsychotic polypharmacy was significantly associated with the pre-metabolic syndrome group (adjusted odds ratio [AOR], 2.348; 95% confidence interval [CI], 1.181-4.668), but not with the metabolic syndrome group (AOR, 1.269; 95%CI, 0.679-2.371). CONCLUSIONS: These results suggest that antipsychotic polypharmacy, compared with monotherapy, may be independently associated with an increased risk of having pre-metabolic syndrome, even after adjusting for patients' lifestyle characteristics. As metabolic syndrome is associated with an increased risk of cardiovascular mortality, further studies are needed to clarify the validity and safety of antipsychotic polypharmacy. BioMed Central 2011-07-26 /pmc/articles/PMC3155482/ /pubmed/21791046 http://dx.doi.org/10.1186/1471-244X-11-118 Text en Copyright ©2011 Misawa et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Misawa, Fuminari
Shimizu, Keiko
Fujii, Yasuo
Miyata, Ryouji
Koshiishi, Fumio
Kobayashi, Mihoko
Shida, Hirokazu
Oguchi, Yoshiyo
Okumura, Yasuyuki
Ito, Hiroto
Kayama, Mami
Kashima, Haruo
Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
title Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
title_full Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
title_fullStr Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
title_full_unstemmed Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
title_short Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
title_sort is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155482/
https://www.ncbi.nlm.nih.gov/pubmed/21791046
http://dx.doi.org/10.1186/1471-244X-11-118
work_keys_str_mv AT misawafuminari isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy
AT shimizukeiko isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy
AT fujiiyasuo isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy
AT miyataryouji isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy
AT koshiishifumio isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy
AT kobayashimihoko isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy
AT shidahirokazu isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy
AT oguchiyoshiyo isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy
AT okumurayasuyuki isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy
AT itohiroto isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy
AT kayamamami isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy
AT kashimaharuo isantipsychoticpolypharmacyassociatedwithmetabolicsyndromeevenafteradjustmentforlifestyleeffectsacrosssectionalstudy